Medivir AB (0GP7) H1 2026 Report: FLEX-HCC Trial Initiated, SEK 140m Capital Raised, MIV-711 Targeting Perthes Disease Expansion

Medivir AB (0GP7) H1 2026 Report: FLEX-HCC Trial Initiated, SEK 140m Capital Raised, MIV-711 Targeting Perthes Disease Expansion →

Medivir AB (Nasdaq Stockholm: MVIR), the Swedish biopharmaceutical company specializing in oncology and rare diseases, released its interim report for January to June 2026, reporting a cash balance of SEK 253.5 million following a fully sub…